Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan

NCT02975882 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02975882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02975882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
August 15, 2017
Completion date
December 31, 2024
Enrollment
33 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

childhood solid neoplasm, recurrent malignant solid neoplasm, recurrent primary central nervous system neoplasm, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm